retatrutide dosage clinical trials retatrutide trial weight loss data Results: 24% in 48 Weeks dose: the complete guide – Retatrutide Dosing: Early Clinical Trial

Importantly, Retatrutide's unique triple receptor agonismtargeting GLP-1, GIP, and glucagon receptorsappears well-tolerated, with adverse events largely consistent with known effects from the broader GLP-1 class, primarily mild gastrointestinal symptoms such as nausea, decreased appetite, and occasional diarrhea, typically resolving within a few weeks of initiation

Eating bland foods, staying hydrated, and avoiding large meals around injection time helps prevent it

If your anticoagulation is managed by a cardiologist or hematologist, ensure they are also aware you are beginning GLP-1 therapy so they can advise on monitoring frequency

When GLP1s suppress appetite, the risk of unintended muscle loss is real unless resistance training and adequate protein intake are prioritized

Appearance and solubility